
Basiliximab Injectable Solution
Form: Injectable Solution
Strength: 20 mg/vial
Reference Brands: Simulect(US)
Category: Transplant
Basiliximab injection, marketed as Simulect, is approved in the US by the FDA and in the EU via EMA for preventing organ rejection in kidney transplantation. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews extensive clinical trial and quality data, while the EMA ensures compliance with safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports timely approval, safe use, and broad availability, helping transplant patients achieve graft survival and improve long-term outcomes worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Cotrimoxazole tablets
Strength: 80 mg trimethoprim / 400 mg sulfamethoxazole
Form: Tablets
Reference Brands: Bactrim, Septra(US & EU)
View Details Get EnquiryAcyclovir tablet
Strength: 200 mg, 400 mg, 800 mg
Form: Tablets
Reference Brands: Zovirax(US & EU)
View Details Get EnquiryBelatacept injection
Strength: 250 mg/vial
Form: Injection
Reference Brands: Nulojix(US)
View Details Get EnquiryPrednisolone syrup
Strength: 15 mg/5ml
Form: Syrup
Reference Brands: Orapred(US)
View Details Get Enquiry